Trial site
Pretoria
Pretoria, Gauteng 0181, South AfricaNot linked to an institution yet
- 14running trials
- 1closed trial
The trials here
What the 15 trials at this site are about, from their registry records.
- Phase
- Phase 313 trials
- Phase 42 trials
- Status
- Active, not recruiting10 trials
- Recruiting4 trials
- Completed1 trial
- Lead sponsor
- Novartis Pharmaceuticals15 trials
Running trials
Recruiting
A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.
NCT05776927· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
NCT06846281· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Recruiting
Phase 3 Extension Study to Evaluate Long-term Safety of Ianalumab in Participants With Systemic Lupus Erythematosus (SIRIUS-SLE Extension).
NCT06133972· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up
NCT05677451· Phase 3· Novartis Pharmaceuticals· Source
Recruiting
A Study to Evaluate the Efficacy and Safety of QMF149 (Indacaterol Acetate/Mometasone Furoate) Versus Budesonide in Children From 6 to Less Than 12 Years of Age With Asthma
NCT05562466· Phase 3· Novartis Pharmaceuticals· Source
Contact: Novartis Pharmaceuticals
Active, not recruiting
A Study of Inclisiran to Prevent Cardiovascular Events in High-risk Primary Prevention Patients.
NCT05739383· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Phase 3 Study to Evaluate Two Regimens of Ianalumab on Top of Standard-of-care Therapy in Patients With Systemic Lupus Erythematosus (SIRIUS-SLE 1)
NCT05639114· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib
NCT05513001· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib (Oral) in Adult Participants (≥18 Years of Age) With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia in Chronic Phase (Ph+ CML-CP)
NCT05456191· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Roll-over Study to Allow Continued Access to Ribociclib
NCT05161195· Phase 4· Novartis Pharmaceuticals· Source
Active, not recruiting
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05156281· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Study of Inclisiran to Prevent Cardiovascular (CV) Events in Participants With Established Cardiovascular Disease
NCT05030428· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS
NCT03650114· Phase 3· Novartis Pharmaceuticals· Source
Active, not recruiting
CINC424A2X01B Rollover Protocol
NCT02386800· Phase 4· Novartis Pharmaceuticals· Source
Recruiting at the same time
How many trials recruit for the same indication here at once. A count, not a rating.
Report an error